SCHEMBL597306

SCHEMBL597306

C#COC[C@H]1O[C@@H](n2ccc(N)nc2=O)C[C@@H]1OP(=O)(O)OP(=O)(O)OP(=O)(O)O

nearest known ligand 0.56

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
POLG P54098 3/20 0.56
POLB P06746 1/20 0.54
P2RY2 P41231 8/20 0.49
P2RY4 P51582 4/20 0.49
P2RY6 Q15077 3/20 0.49
CACNA1F O60840 2/20 0.39
LMNA P02545 2/20 0.39
ALB P02768 2/20 0.39
MAPT P10636 2/20 0.39
CACNA1D Q01668 2/20 0.39
CACNA1S Q13698 2/20 0.39
CACNA1C Q13936 2/20 0.39
PDE3A Q14432 2/20 0.39
P2RY12 Q9H244 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5708921 0.90 POLG (0.54) POLGPOLBP2RY2P2RY4P2RY6
SCHEMBL6141732 0.89 POLG (0.59) POLGPOLBP2RY2P2RY4P2RY6
SCHEMBL9543610 0.88 POLG (0.58) POLGPOLBP2RY2P2RY4P2RY6
SCHEMBL6038227 0.88 POLG (0.57) POLGPOLBP2RY2P2RY4P2RY6
SCHEMBL10902119 0.86 POLG (0.56) POLGPOLBP2RY2P2RY4P2RY6
SCHEMBL25631339 0.85 POLG (0.67) POLGPOLBP2RY2P2RY4P2RY6
SCHEMBL3706290 0.84 POLG (0.54) POLGPOLBP2RY2P2RY4P2RY6
SCHEMBL16468567 0.83 POLG (0.61) POLGPOLBP2RY2P2RY4P2RY6
SCHEMBL22005996 0.83 POLG (0.61) POLGPOLBP2RY2P2RY4P2RY6
SCHEMBL14913972 0.82 DUT (0.51) P2RY2P2RY4P2RY6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2535423-B1 Labeling and detection of nucleic acids LIFE TECHNOLOGIES CORP (US) 2019-05-15 EP disclosed
US-20140336079-A1 LABELING AND DETECTION OF NUCLEIC ACIDS LIFE TECHNOLOGIES CORP (US) 2014-11-13 US disclosed
EP-2535423-A2 Labeling and detection of nucleic acids Life Technologies Corporation (US) 2012-12-19 EP disclosed
EP-2224013-B1 Methods for the determination of telomerase activity using click chemistry LIFE TECHNOLOGIES CORP (US) 2012-12-05 EP disclosed
US-8114636-B2 Labeling and detection of nucleic acids Life Technologies Corporation (US) 2012-02-14 US disclosed
US-20100261181-A1 LABELING AND DETECTION OF NUCLEIC ACIDS Life Technologies Corporation (US) 2010-10-14 US disclosed
EP-2224013-A1 Methods for the determination of telomerase activity using click chemistry Life Technologies Corporation (US) 2010-09-01 EP disclosed
US-20080050731-A1 LABELING AND DETECTION OF NUCLEIC ACIDS INVITROGEN CORPORATION (US) 2008-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100261181-A1 LABELING AND DETECTION OF NUCLEIC ACIDS RNGTT, ADAR, ALKBH1 POLG 762/4885POLB 159/4885P2RY2 2947/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.